Emerging antibiotic-resistant bacteria: Their treatment in total joint arthroplasty

Clinical Orthopaedics and Related Research

Volumn 369, Issue , 1999, Pages 110-123

  Garvin, Kevin L ^a,c   Hinrichs, Steven H ^b   Urban, Joshua A ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; EPEREZOLID; LINEZOLID; METICILLIN; ORITAVANCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIUM ISOLATION; CONFERENCE PAPER; ENTEROCOCCUS; HOSPITAL INFECTION; INFECTIOUS ARTHRITIS; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PREVALENCE; PRIORITY JOURNAL; STAPHYLOCOCCUS; STRAIN DIFFERENCE;

EID: 0032762789     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/00003086-199912000-00012     Document Type: Conference Paper

References (90)

1. Aarestrup FM: Occurrence of glycopeptide resistance among Enterococcus faecium isolates from conventional and ecological poultry farms. Microb Drug Resist 1:255-257, 1995.
2. Aarestrup FM, Ahrens P, Madsen M, et al: Glycopeptide susceptibility among Danish Enterococcus faecium and Enterococcus faecalis isolates of animals and human origin and PCR identification of genes within the Van A cluster. Antimicrob Agents Chemother 40:1938-1940, 1996.
3. Abraham EP, Chain E: An enzyme from bacteria able to destroy penicillin. Nature 146:837-839, 1940.
4. Antti-Poika I, Santavirta S, Konttinen YT, Honkanen V: Outcome of the infected hip arthroplasty. A retrospective study of 36 patients. Acta Orthop Scand 60:670-675, 1989.
5. Bates J, Jordens JZ, Griffiths DT: Farm animals as a putative reservoir for vancomycin-resistant enterococcal infection in man. J Antimicrob Chemother 34:507-514, 1994.
6. Buchholz HW, Elson RA, Engelbrecht E, et al: Management of deep infection of total hip replacement. J Bone Joint Surg 63B:342-353, 1981.
7. Carlsson ÅAS, Josefsson G, Lindberg L: Revision with gentamicin-impregnated cement for deep infections in total hip arthroplasties. J Bone Joint Surg 60A:1059-1064, 1978.
8. Centers for Disease Control: National nosocomial infection surveillance (NNIS) system: Rate of vancomycin-resistant enterococci, by intensive care unit status. MMWR Morb Mortal Wkly Rep 42:597-599, 1993.
9. Centers for Disease Control: Reduced susceptibility of Staphylococcus aureus to vancomycin-Japan. MMWR Morb Mortal Wkly Rep 46:624-628, 1997.
10. Centers for Disease Control: Update: Staphylococcus aureus with reduced susceptibility to vancomycin-United States. MMWR Morb Mortal Wkly Rep 46:813-815, 1997.
11. Chadwick PR, Woodford N, Kaczmarski EB, et al: Glycopeptide-resistant enterococci from uncooked meat. J Antimicrob Chemother 38:908-909, 1996.
12. Chambers HF: Methicillin resistance in staphylococci: Molecular and biochemical basis and clinical implications. Clin Microbiol Rev 10:781-791, 1997.
13. Chambers HF: Parenteral Antibiotics for Treatment of Bacteremia and Other Serious Staphylococcal Infections. In Crossley KB, Archer GL (eds). The Staphylococci in Human Disease. New York, NY, Churchill Livingstone Inc 583-601, 1997.
14. Chant C, Rybak MJ: Quinupristin/dalfopristin (RP 59500): A new streptogramin antibiotic. Ann Pharmacother 29:1022-1027, 1995.
15. Chuard C, Herrmann M, Vaudaux P, et al: Successful treatment of experimental chronic foreign body infection due to Methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob Agents Chemother 35:2611-2616, 1991.
16. Collins LA, Malanoski GJ, Elipoulos GM, et al: In vitro activity of RP59500; An injectable streptogramin antibiotic against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother 37:598-601, 1993.
17. Colebrook L, Kenny M: Treatment with prontosil of puerperal infections due to haemolytic streptococci. Lancet 2:1319-1322, 1936.
18. Coque TM, Tomayko JF, Ricke SC, Okhyusen PC, Murray BE: Vancomycin-resistant Enterococci from nosocomial, community, and animal cources in the United States. Antimicrob Agents Chemother 40: 2605-2609, 1996.
19. Craven DE, Kollisch NR, Hsieh CR, et al: Vancomycin treatment of bacteremia caused by oxacillin-resistant Staphylococcus aureus: Comparison with beta-lactam antibiotic treatment of bacteremia caused by oxacillin-susceptible Staphylococcus aureus. J Infect Dis 147:137-143, 1983.
20. Crean TF: The use of prontosil in the treatment of gonorrhoeae. Lancet 2:895-898, 1937.
21. Devriese LA, Ieven M, Goossens H, et al: Presence of vancomycin-resistant Enterococci in farm and pet animals. Antimicrob Agents Chemother 40:2285-2287, 1996.
22. Domagk G: Ein Beitrag zur Chemotherapie der bakteriellen Infektionen. Dtsch Med Wochenschr 61:250-253, 1935.
23. Dominguez EA, Davis JC, Langnas AN, et al: An outbreak of vancomycin-resistant Enterococcus faecium in liver transplant recipients. Liver Transpl Surg 3:586-590, 1997.
24. Dresser LD, Rybak MJ: The pharmacologic and bacteriologic properties of Oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 18:456-462, 1998.
25. Duncan CP, Masri BA: The role of antibiotic-loaded cement in the treatment of an infection after a hip replacement. J Bone Joint Surg 76A:1742-1751, 1994.
26. Dworkin RJ, Lee BL, Sande MA, Chambers HF: Ciprofloxacin with Rifampin: A predominantly oral regimen for right-sided Staphylococcus aureus endocarditis in intravenous drug abusers. Lancet 2:1071-1073, 1989.
27. Elson RA: One-stage exchange in the treatment of the infected total hip arthroplasty. Semin Arthroplasty 5:137-141, 1994.
28. Entenza JM, Drugeon H, Glauser MP, Moreillon P: Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500. Antimicrob Agents Chemother 39:1419-1424, 1995.
29. Fantin B, Leclercq R, Merle Y, et al: Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (Quinupristin-Dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrob Agents Chemother 39:400-405, 1995.
30. Fass RJ: In vitro activity of RP 59500, A semisynthetic injectable pristinamycin, against Staphylococci, Streptococci, and Enterococci. Antimicrob Agents Chemother 35:553-559, 1991.
31. Fitzgerald Jr RH: Infected total hip arthroplasty: Diagnosis and treatment. J Am Acad Orthop Surg 33:249-262, 1995.
32. Garcia-Garrote F, Cercenado E, Alcala L, Bouza E: In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates. Antimicrob Agents Chemother 42:2452-2455, 1998.
33. Gardner P, Smith DH, Beer H, et al: Recovery of resistance (R) factors from a drug-free community. Lancet 1:300-301, 1970.
34. Garvin KL, Evans BG, Salvati EA, Brause BD: Palacos gentamicin for the treatment of deep periprosthetic hip infections. Clin Orthop 298:97-105, 1994.
35. Garvin KL, Fitzgerald Jr RH Salvati EA, et al: Reconstruction of the infected total hip and knee arthroplasty with gentamicin-impregnated Palacos bone cement. Instr Course Lect 42:293-302, 1993.
36. Gilbert DN, Wood CA, Kimbrough RC: Failure of treatment with teicoplanin at 6 milligrams/ kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon. Antimicrob Agents Chemother 35:79-87, 1991.
37. Goossens H: Spread of vancomycin-resistant Enterococci: Differences between the United States and Europe. Infect Control Hosp Epidemiol 19:546-551, 1998.
38. Harle A: Infection management in total hip replacement. Arch Orthop Trauma Surg 108:63-71, 1989.
39. Heldman AW, Hartert TV, Ray SC, et al: Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: Prospective randomized comparison with parenteral therapy. Am J Med 101:68-76, 1996.
40. Hirakawa K, Stulberg BN, Wilde AH, Bauer TW, Secic M. Results of 2-stage reimplantation for infected total knee arthroplasty. J Arthroplasty 13:22-28, 1998.
41. Hiramatsu K, Aritaka N, Hanaki H, et al: Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673, 1997.
42. Hope PG, Kristinsson KG, Norman P, Elson RA: Deep infection of cemented total hip arthroplasties caused by coagulase-negative Staphylococci. J Bone Joint Surg 71B:851-855, 1989.
43. Hospital Infection Control Practices Advisory Committee: Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 16:105-113, 1995.
44. Hovelius L, Josefsson G: An alternative method of exchange operation of infected arthroplasty. Acta Orthop Scand 50:93-96, 1979.
45. Hunter GA: The results of reinsertion of a total joint prosthesis after sepsis. J Bone Joint Surg 61B:422-423, 1979.
46. Ivarsson I, Wahlstrom O, Djerf K, Jacobsson SA: Revision of infected hip replacement. Two-stage procedure with a temporary gentamicin spacer. Acta Orthop Scand 65:7-8, 1994.
47. Iwen, PC, Kelly DM, Linder J, Hinrichs SH: Change in prevalence and antibiotic resistance of Enterococcus species isolated from blood cultures over an 8-year period. Letter. Antimicrob Agents Chemother 41:494-495, 1997.
48. Jacoby GA, Archer GL: New mechanisms of bacterial resistance to antimicrobial agents. New Engl J Med 324:601-612, 1991.
49. James PJ, Butcher IA, Gardner ER, et al: Methicillin-resistant Staphylococcus epidermidis in infection of hip arthroplasties. J Bone Joint Surg 768:725-727, 1994.
50. Jones RN, Barrett MS, Erwin ME: In vitro activity and spectrum of LY333328; A novel glycopeptide derivative. Antimicrob Agents Chemother 41:488-493, 1996.
51. Katz RP, Callaghan JJ, Johnston RC: A minimum ten year follow-up study of one stage reimplantation of the infected total hip. Orthop Trans 18:993, 1994.
52. Ketterl R, Henley MB, Stübinger B, Beckurts T, Claudi B: Analysis of three operative techniques for infected total hip replacements. Orthop Trans 12:715, 1988.
53. Kirby WM: Extraction of a highly potent penicillin inactivator from penicillin-resistant Staphylococci. Science 99:452-455, 1944.
54. Kirby WM, Perry DM, Bauer AW: Treatment of Staphylococcal septicemia with vancomycin: Report of 33 Cases. N Engl J Med 262:49-55, 1960.
55. Klare I, Heier H, Claus H, et al: Enterococcus faecium strains with Van A-mediated high-level glycopeptide resistance isolated from animal foodstuffs and fecal samples of humans in the community. Microb Drug Resist 1:265-272, 1995.
56. Klare I, Heier H, Claus H, Reissbodt R, Witte W: Van A-mediated high-level glycopeptide resistance in Enterococcus faecium from animal husbandry. FEMS Microbial Lett 125:165-172, 1995.
57. Klastersky J, Coppens L, van der Auwera P, Meunier-Carpenteir F: Vancomycin therapy of oxacillin-resistant Staphylococcus aureus infection. J Antimicrob Chemother 11:361-367, 1983.
58. th Interscience Conference on Antimicrobial Agents and Chemotherapy 275:1023, 1987. Abstract.
59. Levine DP, Cushing RD, Jui J, Brown WJ: Community-acquired methicillin-resistant Staphylococcus aureus Endocarditis in the Detroit Medical Center. Ann Intern Med 97:330-338, 1982.
60. Levine DP, Fromm BS, Reddy BR: Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 115:674-680, 1991.
61. Lieberman JR, Callaway GH, Salvati E, Pellicci PM, Brause BD: Treatment of the infected total hip arthroplasty with a two-stage reimplantation protocol. Clin Orthop 301:205-212, 1994.
62. Lindberg L: The experience with antibiotic cement in Sweden. Orthop Trans 5:371, 1981.
63. Loty B, Postel M, Evrard J, et al: Remplacements en un temps des protheses totales de hanches infectees et recontronstructions osseuses par allogreffes. Etude de 90 reprises dont 46 avec allogreffes osseuses. Int Orthop 16:330-338, 1992.
64. Low DE: Quinupristin/Dalfopristin: Spectrum of activity, pharmocokinetics, and initial clinical experience. Microb Drug Resist 1:223-234, 1995.
65. Miley GB, Scheller Jr AD, Turner RH: Medical and surgical treatment of the septic hip with one-stage revision arthroplasty. Clin Orthop 170:76-82, 1982.
66. Murray BE: Vancomycin-resistant Enterococci. Am J Med 102:284-293, 1997.
67. Murray WR: Use of antibiotic-containing bone cement. Clin Orthop 190:89-95, 1984.
68. Myers JP, Linnemann Jr CC: Bacteremia due to methicillin-resistant Staphylococcus aureus. J Infect Dis 145:532-536, 1982.
69. Nasser S, Lee YF, Amstutz HC: Direct exchange arthroplasty in 30 septic total hip replacements without recurrent infection. Orthop Trans 13:519, 1989.
70. Neu HC, Chin N, Gu J: The In-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination. J Antimicrob Chemother 30(Suppl):83-94, 1992.
71. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 72:195-198, 1992.
72. Sanzén L, Carlsson AAS, Josefsson G, Lindberg LT: Revision operations on infected total hip arthroplasties. Two-to-nine-year follow-up study. Clin Orthop 229:165-172, 1988.
73. Schaechter M, Eisenstein BI: Genetics of Bacteria. In Schaechter M, Medoff G, Eisenstein BI, (eds). Mechanism of Microbial Disease. Baltimore, Williams and Wilkins 57-76, 1993.
74. Schwalbe RS, Stapleton JT, Gilligan PH: Emergence of vancomycin resistance in coagulase-negative Staphylococci. N Engl J Med 316:927-931, 1987.
75. Silverman J, Thal LA, Perri MB, Bostic G, Zervos MJ: Epidemiologic evaluation of antimicrobial resistance in community-acquired enterococci. J Clin Microbiol 36:830-832, 1998.
76. Small PM, Chambers HF: Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 34:1227, 1990.
77. Sorrell TC, Packham DR, Shanker S, et al: Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med 97:344-350, 1982.
78. th General Meeting of the American Society for Microbiology. Am Soc Microbiol 59:143, 1996. Abstract.
79. Tabaqchali S: Vancomycin-resistant Staphylococcus aureus: Apocalypse now? Lancet 350:1644-1645, 1997.
80. Torres C, Reguera JA, Sammartin MJ, Perez-Diaz JC, Baquero F: Van A mediated vancomycin-resistant Enterococcus ssp in sewage. J Antimicrob Chemother 33:553-561, 1994.
81. Tuazon CU, Miller H: Clinical and microbiologic aspects of serious infections caused by Staphylococcus epidermidis. Scand J Infect Dis 15:347-360, 1983.
82. Uttley AHC, Collins CH, Naidoo J, George RC: Vancomycin-resistant Enterococci. Lancet 1:57-58, 1988.
83. Van der Auwera P, Pensart N, Korten V, Murray BE, Leclercq R: Influence of oral glycopeptides on the fecal flora of human volunteers: Selection of highly glycopeptide-resistant Enterococci. J Infect Dis 173:1129-1136, 1996.
84. Veach LA, Pfaller MA, Barren M, Koontz FP, Wenzel RP: Vancomycin esistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. J Clin Microbiol 28:2064-2068, 1990.
85. Vincent S, Minkler P, Bincziewski B, Etter L, Shlaes DM: Vancomycin resistance in Enterococcus gallinarum. Antimicrob Agents Chemother 36:1392-1399, 1992.
86. Wegener HC, Madsen M, Nielsen N, Aarestrup FM: Isolation of vancomycin resistant Enterococcus faecium from food. Int J Food Microbiol 35:57-66, 1997.
87. Witte W, Braulke C, Heuck D, Cuny C: Analysis of nosocomial outbreaks with multiply and methicillin-resistant Staphylococcus aureus (MRSA) in Germany: Implications for hospital hygiene Infection 22:(Suppl 2) S128-134, 1994.
88. Witte W, Klare I: Glycopeptide-resistant Enterococcus faecium outside hospitals: A commentary. Microb Drug Resist 1:259-263, 1995.
89. Woodford N: Glycopeptide-resistant Enterococci: A decade of experience. J Med Microbiol 47:849-862, 1998.
90. Wroblewski BM: One-stage revision of infected cemented total hip arthroplasty. Clin Orthop 211:103-107, 1986.